This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen
Diverse Companies Join Forces to Fight Coronavirus Menace
by Payal Jalan
Nervousness related to the coronavirus outbreak is visible across the economies worldwide. Amid the pandemic, many corporates have come together to help contain the outbreak.
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
by Zacks Equity Research
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
by Zacks Equity Research
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Regeneron Up on Identification of Antibodies for Coronavirus
by Zacks Equity Research
Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.
Gilead Up as Remdesivir Shows Promise in Treating Coronavirus
by Zacks Equity Research
Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.
Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up
by Kaibalya Pravo Dey
While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway
Top Analyst Reports for Amazon, IBM & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), International Business Machines Corporation (IBM) and Biogen Inc. (BIIB).
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies
by Zacks Equity Research
Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies
Stocks the Pros Loved Heading into 2020
by Tracey Ryniec
As stocks hit new all-time highs to finish 2019, the professional money managers were busy positioning their portfolios for 2020. What were they buying, and selling, heading into the new year?
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen
Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas
by Sanghamitra Saha
Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?